AbbVie

NYSE ABBV · North Chicago, IL

Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health

AbbVie is a clinical trial sponsor based in North Chicago, IL, listed as NYSE ABBV. It has 238 active clinical trials with 94,591 planned participants, across 16 therapeutic areas. Since 2021 it has completed 416 trials and stopped 82 early. Its FDA record on file shows 2 inspections.

Trial track record · since 2021

238Active trials94,591 planned participants
416Completed207 with results posted
82Stopped early16% of finished trials

FDA record

2InspectionsLatest 2026-04-27: No action indicated · 2 NAI
0Warning lettersNone on file
0RecallsNone on file

Recent FDA actions

Financials · NYSE ABBV

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Fundraising

Pipeline · 238 active trials

StageTrialStatus

On the market

66 approved drug applications with a product on the market.

Questions about AbbVie

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-11-06.

The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.

Approve Suite is not affiliated with AbbVie.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.